Eden Research plc Result of AGM (5096C)

TIDMEDEN

RNS Number : 5096C

Eden Research plc

28 June 2016

28 June 2016

Eden Research Plc

("Eden" or the "Company")

Result of AGM

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that at the AGM of Eden held today at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED, all the resolutions were duly passed.

Enquiries

 
Eden Research plc               www.edenresearch.com 
Sean Smith, Chief Executive       Tel: [phone] 
 Officer 
Alex Abrey, Chief Financial 
 Officer 
 
Shore Capital and Corporate         www.shorecap.com 
 Limited 
Stephane Auton/Patrick Castle     Tel: [phone] 
 
Walbrook PR Ltd                Tel: [phone] or 
                                 [e-mail] 
Paul McManus                      Mob: [phone] 
Lianne Cawthorne                  Mob: [phone] 
 

About Eden Research

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic hydrophobic compounds. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of GBP12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into licence agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has already been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain and Italy.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFPMBTMBTTBFF

(END) Dow Jones Newswires

June 28, 2016 07:28 ET (11:28 GMT)